|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 230,000.00 KRW | +4.55% |
|
+13.30% | +27.07% |
| 02-05 | CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5) | RE |
| 01-30 | Celltrion Launches Autoimmune Drug Aptozma in Europe | MT |
Business description: Celltrion, Inc.
Number of employees: 2,680
Sales by Activity: Celltrion, Inc.
| Fiscal Period: December | 2020 (KRW) | 2021 (KRW) | 2022 (KRW) | 2023 (KRW) | 2024 (KRW) |
|---|---|---|---|---|---|
Biopharmaceutical | 1,690B | 1,616B | 1,937B | 1,873B | 6,070B |
Chemical Drugs | 242B | 557B | 654B | 501B | 531B |
Other | 2.63B | 3.05B | 3.88B | 5.14B | 5.82B |
Amount Removed between Sectors | -85.76B | -264B | -311B | -203B | -3,050B |
Geographical breakdown of sales: Celltrion, Inc.
| Fiscal Period: December | 2020 (KRW) | 2021 (KRW) | 2022 (KRW) | 2023 (KRW) | 2024 (KRW) |
|---|---|---|---|---|---|
South Korea | 1,542B | 2,015B | 2,324B | 2,262B | 4,184B |
Europe | - | - | - | - | 1,862B |
Asia | - | 76.42B | 140B | 117B | 252B |
North America | - | - | - | - | 168B |
Central and South America | - | - | - | - | 141B |
Americas | - | 84.61B | 131B | - | - |
Overseas | 308B | - | - | - | - |
Consolidation Adjustment | - | -264B | -311B | -203B | -3,050B |
Executive Committee: Celltrion, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | - | 19/03/2015 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 51 | - |
Sung-Han Lee
CMP | Compliance Officer | 44 | - |
Yoon-Mo Koo
PRN | Corporate Officer/Principal | 56 | - |
Sang-Joon Lee
PRN | Corporate Officer/Principal | 59 | - |
Composition of the Board of Directors: Celltrion, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Jung-Jin Seo
CHM | Chairman | 68 | - |
Dong-Il Kim
BRD | Director/Board Member | 67 | 16/07/2008 |
Joseph Lee
BRD | Director/Board Member | 67 | 16/07/2008 |
Gyun-Seok Cho
BRD | Director/Board Member | 66 | 19/03/2009 |
Byung-Hoon Jeon
BRD | Director/Board Member | 68 | 26/03/2014 |
Jong-Seok Lee
BRD | Director/Board Member | 73 | 07/12/2014 |
Geun-Young Kim
BRD | Director/Board Member | 66 | - |
Dae-Hyeon Yoo
BRD | Director/Board Member | 67 | - |
Soon-Woo Lee
BRD | Director/Board Member | 75 | - |
Jae-Sik Lee
BRD | Director/Board Member | 68 | - |
Holdings: Celltrion, Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
CELLTRION PHARM, INC. 54.8% | 24,416,242 | 54.8% | 1 240 M $ |
CELLTRION, INC. 3.1% | 7,170,560 | 3.1% | 1 046 M $ |
BIOTOXTECH CO., LTD. 10.22% | 1,631,134 | 10.22% | 3 M $ |
Company details: Celltrion, Inc.
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.55% | +13.30% | +33.18% | +51.67% | 34.53B | |
| +0.54% | -0.54% | -14.24% | -4.49% | 47.17B | |
| -1.43% | +1.12% | +56.09% | +40.18% | 38.6B | |
| +2.76% | -16.68% | -7.43% | -16.34% | 32.68B | |
| -0.77% | -0.43% | +129.30% | +283.13% | 18.7B | |
| -2.16% | -9.83% | +49.77% | +135.13% | 14.94B | |
| +0.09% | -0.88% | +30.49% | -0.30% | 14.13B | |
| Average | +0.51% | -1.56% | +39.59% | +69.85% | 28.68B | |
| Weighted average by Cap. | +0.86% | -1.01% | +29.83% | +49.31% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- A068270 Stock
- Company Celltrion, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition